Integrative analysis reveals gut microbiota-associated host regulatory networks in liver fibrosis
Frontiers in Cellular and Infection Microbiology · 2026
DOI: 10.3389/fcimb.2026.1963640 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Cellular and Infection Microbiology, 2026. Verfasst von Shiyu Peng und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology, The First Affiliated Hospital of Xinjiang Medical University, Urumqi, Xinjiang, China. Hauptthemen laut MEDLINE: Liver Cirrhosis, Gastrointestinal Microbiome, Gene Regulatory Networks. Die Arbeit nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Gut microbiota-derived metabolites may contribute to liver fibrosis by affecting host inflammatory, metabolic, and epigenetic pathways. We aimed to identify microbiota-associated host genes shared across liver fibrosis of different etiologies.
Methods
Microbiota- and metabolite-associated host genes were obtained from gutMGene v2.0 and integrated with differentially expressed genes from two human liver transcriptomic datasets: GSE84044 for HBV-related fibrosis and GSE49541 for NAFLD-related fibrosis. Shared genes were analyzed using protein–protein interaction and functional enrichment analyses. Selected metabolite–protein interactions were assessed by molecular docking and molecular dynamics simulations. Two-sample Mendelian randomization was used to examine potential associations between candidate gene expression and liver fibrosis risk.
Results
Fourteen microbiota-associated genes were differentially expressed in both fibrosis cohorts, including CCL2, CCL20, CXCL6, PTGS2, HDAC2, HDAC3, ADRA2A, SOD1, PEMT, and GNMT. These genes were mainly associated with chemokine activity, histone deacetylation, and IL-17 and TNF signaling. Molecular docking suggested structural compatibility between phenylacetylglutamine and ADRA2A, while butyrate showed weaker predicted interactions with HDAC2 and HDAC3.Molecular dynamics analysis supported the stability of the ADRA2A–phenylacetylglutamine complex under the simulated conditions. Mendelian randomization identified nominal associations of HDAC3, CCL2, PTGS2, and VCL expression with liver fibrosis risk.
Conclusions
This study identified shared microbiota-associated host regulatory candidates in HBV- and NAFLD-related liver fibrosis.HDAC3 and ADRA2A may represent potential links between microbial metabolic signals and fibrotic responses, although further experimental validation is required.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Gastroenterology, The First Affiliated Hospital of Xinjiang Medical University, Urumqi, Xinjiang, China.
- Department of Gastroenterology, The First Affiliated Hospital of Shihezi University, Shihezi, Xinjiang, China.
- Department of Infectious Diseases, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, Shandong, China.
- Department of Central Laboratory, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, Shandong, China.
Zitieren
APA
Peng, S., Nie, Y., Song, Y., Ding, H., Cao, H., Wu, H., Qi, J., & Zhu, Q. (2026). Integrative analysis reveals gut microbiota-associated host regulatory networks in liver fibrosis. Frontiers in Cellular and Infection Microbiology. https://doi.org/10.3389/fcimb.2026.1963640
Vancouver
Peng S, Nie Y, Song Y, Ding H, Cao H, Wu H, et al. Integrative analysis reveals gut microbiota-associated host regulatory networks in liver fibrosis. Frontiers in Cellular and Infection Microbiology. 2026. doi:10.3389/fcimb.2026.1963640
BibTeX
@article{Peng2026,
author = {Peng, Shiyu and Nie, Yingying and Song, Yuzhu and Ding, Han and Cao, Huiling and Wu, Hao and Qi, Jianni and Zhu, Qiang},
title = {Integrative analysis reveals gut microbiota-associated host regulatory networks in liver fibrosis},
journal = {Frontiers in Cellular and Infection Microbiology},
year = {2026},
doi = {10.3389/fcimb.2026.1963640}
}
EUVIMED